Abstract

Objectives: Abacavir is a nucleoside analog reverse transcriptase inhibitor (NRTI), antiretroviral drug; it is used in treatment of AIDS. The present study deals with the formulation and evaluation of Abacavir nanoparticles. Methods: Abacavir nanoparticles were formulated by solvent displacement method using Eudragit RL-100, chitosan and Poloxamer-188. Nanoparticles were characterized by determining its particle size, drug entrapment efficiency, particle morphological character and in-vitro drug release. Results: Particle size range of nanoparticles was in the range of 121.4-140.6 nm. Zeta potential of formulations was determined, and it was found in range of 16.5-20.45 mv. The in-vitro release of nanoparticles were carried out which exhibited a sustained release of Abacavir from nanoparticles up to 10 hrs. Conclusion: The study concludes that nanoparticles can be a promising drug delivery system for sustained release of Abacavir in terms of increased bioavailability. Peer Review History: Article received on- 15 November Revised on- 10 December Accepted on- 15 December, Available online 15 January 2017 UJPR follows the most transparent and toughest ‘Advanced OPEN peer review’ system. The identity of the authors and, reviewers will be known to each other. This transparent process will help to eradicate any possible malicious/purposeful interference by any person (publishing staff, reviewer, editor, author, etc) during peer review. As a result of this unique system, all reviewers will get their due recognition and respect, once their names are published in the papers. We expect that, by publishing peer review reports with published papers, will be helpful to many authors for drafting their article according to the specifications. Auhors will remove any error of their article and they will improve their article(s) according to the previous reports displayed with published article(s). The main purpose of it is ‘to improve the quality of a candidate manuscript’. Our reviewers check the ‘strength and weakness of a manuscript honestly’. There will increase in the perfection, and transparency. Received file: Reviewer's Comments: Average Peer review marks at initial stage: 4.0/10 Average Peer review marks at publication stage: 7.0/10 Reviewer(s) detail: Dr. Kingsley C Anukam, University of Benin, Nigeria, kanukam@gmail.com Dr. Iman Muhammad Higazy, National Research Center, Egypt, imane.higazy@hotmail.com Similar Articles: NANOSPONGES: A NEW ERA OF VERSATILE DRUG DELIVERY SYSTEM

Highlights

  • Preparation of Abacavir nanoparticles Abacavir nanoparticles were prepared by the solvent displacement method

  • Four different Abacavir nanoparticles formulations were prepared by the solvent displacement method with varying proportions of Eudragit RL-100, and chitosan

  • The scanning electron microphotograph indicate that Abacavir nanoparticles have a discrete spherical structure without aggregation

Read more

Summary

Objectives

Abacavir is a nucleoside analog reverse transcriptase inhibitor (NRTI), antiretroviral drug; it is used in treatment of AIDS. The present study deals with the formulation and evaluation of Abacavir nanoparticles. Methods: Abacavir nanoparticles were formulated by solvent displacement method using Eudragit RL-100, chitosan and Poloxamer-188. Nanoparticles were characterized by determining its particle size, drug entrapment efficiency, particle morphological character and in-vitro drug release. Results: Particle size range of nanoparticles was in the range of 121.4-140.6 nm. Zeta potential of formulations was determined, and it was found in range of 16.5-20.45 mv. The in-vitro release of nanoparticles were carried out which exhibited a sustained release of Abacavir from nanoparticles up to 10 hrs. Conclusion: The study concludes that nanoparticles can be a promising drug delivery system for sustained release of Abacavir in terms of increased bioavailability.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call